Levetiracetam Noridem (Levetiracetam)

Levetiracetam binds selectively to the synaptic vesicle protein SV2A, which regulates neurotransmitter release. By modulating SV2A function, the drug reduces neuronal excitability and limits the spread of epileptiform activity, thereby helping to prevent seizure generation without directly affecting ion channels or GABA receptors.

The specific dose of Levetiracetam Noridem is determined by the prescribing clinician based on factors such as the patient’s age, weight, renal function, seizure type, and response to therapy. Dosage adjustments are made according to clinical judgment and therapeutic monitoring.

Levetiracetam is classified as pregnancy category B1, indicating that animal studies have not shown risk and there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies the potential risk. Limited data are available for breastfeeding; a risk‑benefit assessment should be performed.

To order Levetiracetam Noridem, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and assistance with import documentation.

Levetiracetam differs from many traditional antiepileptics by targeting the SV2A protein rather than ion channels or GABA receptors. This unique mechanism often results in a favorable drug‑interaction profile and a lower incidence of enzyme‑inducing effects compared with agents such as carbamazepine or phenytoin.

Levetiracetam Noridem should be stored at ambient temperature, below 25 °C, in its original packaging. The container should be kept away from direct sunlight, moisture and sources of heat to maintain product stability.

The product is supplied as an intravenous solution and is administered by slow infusion into a peripheral or central vein under the supervision of a qualified healthcare professional. The infusion rate and total daily dose are set by the prescriber according to the patient’s clinical needs.

The most serious risks associated with levetiracetam include severe allergic reactions such as anaphylaxis, skin disorders like Stevens‑Johnson syndrome, and rare hematologic abnormalities. Clinicians should monitor patients for signs of rash, swelling, respiratory distress, or unexplained changes in blood counts and act promptly if they occur.

Levetiracetam Noridem should not be used in patients with known hypersensitivity to levetiracetam or any component of the formulation. Caution is also advised for individuals with severe renal impairment who have not been dose‑adjusted, and it is contraindicated in patients where an allergic reaction to the drug has previously occurred.